Article
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism - 1 Sept 2006
Hansen Lars, Ekstrøm Claus T, Tabanera Y Palacios René, Anant Madan, Wassermann Karsten, Reinhardt Rickey R
Abstract excerpt
CONTEXT: Activation of peroxisome proliferator-activated receptors (PPARs)-gamma by thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPARalpha/gamma agonists (pargluva, ragaglitazar) is a widely used pharmacological principle to treat insulin resistance and type 2 diabetes. Clinically, however, fluid retention and edema are worrying side effects with these drugs. OBJECTIVE: The objective of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
